Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

BGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision Medicine


News provided by

Clearbridge BioMedics

16 May, 2016, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

SHENZHEN, China, May 16, 2016 /PRNewswire/ -- BGI, the world's largest omics organization, has signed a partnership agreement with Singapore-based oncology research and diagnostics company Clearbridge BioMedics (CBB). This aims to develop the CTC (circulating tumor cell) liquid biopsy market in China, including Mainland China, Hong Kong and Macao. BGI will work together with CBB to solely distribute and market the ClearCell® FX1 solution and related products in China, extend this technology into clinical and cutting-edge research applications, and develop clinical products. The ClearCell® technology is a label-free, automated system that is able to isolate and enrich intact, viable rare cells from a patient's blood sample.

This joint collaboration aims to develop an integrated CTC liquid biopsy solution by leveraging BGI's strengths from genomics to trans-omics and CBB's expertise in rare cell separation, in order to provide more actionable clinical insights through a simple blood draw. BGI is establishing a dedicated team to ensure this trans-omics science and technology is successfully translated into precision medicine. This team will provide an innovative end-to-end solution for omics analysis or genetic profiling at the single cell level from extremely rare cells in clinical samples.

The collaborative research agreement focuses on major types of cancer in China, such as lung, breast, and liver. BGI and CBB will collaborate to drive clinical adoption by working with key opinion leaders in leading hospitals in order to expand the CTC technology and genomic applications. Possible applications include cancer-related targeted gene analysis, drug-related gene analysis, single cell analysis and cancer immunotherapy.

"We believe that liquid biopsy plays a key role in clinical diagnostics and personalized medicine and can potentially even aid in immunotherapy PD-L1 treatment management. BGI is a global leader in the genomics and precision medicine space, and this collaboration supports our efforts to bring our ClearCell® FX1 System into the China research and clinical markets. We are convinced their strong network, track record and excellent capabilities complement our execution and align with our strategic vision for China," said Mr Johnson Chen, Chairman and Founder of Clearbridge BioMedics.

"BGI's goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating an array of leading technologies. This includes BGISEQ series sequencers for genomics, economies of scale for sample storage and bioinformatics for IT and computing resources. Liquid biopsy, a critical cancer sample format which enables access to extremely rare cells such as CTC, will enable us to study cancer genome and diseases at the single cell level. Having worked closely with Clearbridge BioMedics for the last few years, we are very confident that the combination of their rare cell enrichment technology with BGI's genomic and trans-omics technology, and our strong collaboration networks including joint labs in top hospitals and global alliances based on BGISEQ sequencers, will result in better cancer management. We hope to accelerate the adoption of precision medicine in China, to better serve the needs of patients," said Dr. Xun Xu, Executive Vice President of BGI and Director of BGI Research.

About Clearbridge BioMedics

Clearbridge BioMedics is a clinical stage oncology research and diagnostics company that enables real-time liquid biopsy using a label-free rare-cell CTC enrichment platform. It is a National University of Singapore (NUS) spin-off company that is committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX1 System, using the CTChip®, is based on novel microfluidics technology that effectively isolates intact and viable CTCs from patients' blood. The system uses Dean flow fractionation for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells that could be used for cancer screening, diagnosis, staging, personalized medicine and treatment monitoring. Utilizing the next generation non-invasive liquid biopsy to analyze blood samples for CTCs, the device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine.

Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics attained ISO 13485 certification in 2011.

Company website: www.clearbridgebiomedics.com. Introductory video: http://youtu.be/aRBuOxLfX3g

About BGI

BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 1,500 publications, many in top-tier journals such as Nature and Science.

BGI's distinguished achievements have made a significant contribution to the development of genomics throughout the world. BGI's goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry's broadest array of leading technologies, including BGI's own BGISEQ sequencing platform, economies of scale, and expert bioinformatics resources.

BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. BGI's services and solutions are available in more than 50 countries around the world.

Company website: www.genomics.cn.

Contacts:

CBB:
Chan Yiu Lin (Ms)
Greener Grass Communications
Mobile: (+65) 9765 5897
Email: media@clearbridgeaccelerator.com

Gwendolene Yeo (Ms)
Business Development Director
Mobile: (+65) 8699 9291
Email: gwendolene@clearbridgebiomedics.com

BGI:

Luting Song (Mr)
Mobile: (+86) 183 2074 7285
Email: songluting@genomics.cn

Bicheng Yang, Ph.D.
Public Communication Officer
Mobile: (+86) 755 8263 9701
Email: yangbicheng@genomics.cn

Related Links

http://www.genomics.cn/

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.